First Tracks Biotherapeutics reported financial results for the three and six months ended June 30, 2026. The company held $168.0 million in cash, cash equivalents, and investments as of June 30, 2026. Research and development expenses were $25.6 million for the quarter and $59.6 million for the six-month period, while general and administrative expenses rose to $9.3 million and $28.1 million respectively due to separation-related legal costs. The net loss was $33.4 million ($0.95 per share) for the quarter and $83.9 million ($2.40 per share) for the six-month period. Clinically, the U.S. FDA granted Fast Track designation for ANB033 in celiac disease, Cohort 1 enrollment is complete with top-line data expected in Q4 2026, and Cohort 2 data is anticipated in Q1 2027. The company maintains a cash runway into Q2 2028. First Tracks Biotherapeutics operates as a clinical-stage biotechnology company developing antibody therapeutics for autoimmune and inflammatory diseases.